Short Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Rises By 20.7%

PDS Biotechnology Co. (NASDAQ:PDSB) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 4,670,000 shares, a growth of 20.7% from the February 13th total of 3,870,000 shares. Approximately 13.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 630,100 shares, the days-to-cover ratio is presently 7.4 days.

PDS Biotechnology Stock Up 3.7 %

Shares of NASDAQ PDSB traded up $0.05 during mid-day trading on Tuesday, reaching $1.39. 387,683 shares of the company were exchanged, compared to its average volume of 568,546. PDS Biotechnology has a 1 year low of $1.13 and a 1 year high of $5.00. The stock has a market cap of $53.09 million, a price-to-earnings ratio of -1.20 and a beta of 1.68. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average of $1.43 and a 200 day moving average of $2.24.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PDSB. B. Riley decreased their price objective on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PDSB. Two Sigma Investments LP boosted its position in shares of PDS Biotechnology by 273.5% in the 4th quarter. Two Sigma Investments LP now owns 65,732 shares of the company’s stock worth $107,000 after purchasing an additional 48,132 shares in the last quarter. Jane Street Group LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth about $58,000. Marshall Wace LLP grew its stake in PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after purchasing an additional 10,837 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of PDS Biotechnology during the 4th quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC boosted its position in PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after purchasing an additional 76,800 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.